Ann: First Commerical Pancreas Treatment In Spain, page-45

look unlike other biotech which first needs to go through CE approvals if trying to sell in EU and then get reimbursement approved the OSL already had step one completed while in Spain they are now on to second step with first commercial sale. word "commercial" is what lifting the price today and if we get more of such news then it will help share price... in my opinion.

This is the best I found online about number of Pancreatic cancer diagnosed in Spain @ 8700 in 2021. If you use 2% of this 8700 then it's around 174 and then say if device is sold for 30,000 AUD (roughly 20k to 25k EUR) then it will take you to roughly revenue of around $5m revenue just from 1 company. Now this is long shot because getting most people to use requires number of successful usage and history so it will take time and only happens if devices is proven to extend life span or other medical criteria hospital use to reimburse this device in my opinion.... so not saying it will happen tomorrow but all possibility in long run if device is successful and surgeon starts recommending in my opinion.



https://www.imim.es/news/464/new-diagnostic-marker-for-pancreatic-cancer-identified#:~:text=Pancreatic%20cancer%2C%20and%20specifically%20pancreatic,diagnosed%20in%20Spain%20in%202021.